JAKARTA - After successfully closing 2021 with satisfactory financial performance, the manager of Bunda Hospital PT Bundamedik Tbk (BMHS) has consistently developed a health ecosystem aggressively during the transition from pandemic to endemic. In the midst of a significant decline in revenue from COVID-19, the company was also able to record non-COVID revenues of IDR 375 billion during the first quarter of 2022.
"This is the company's highest non-COVID revenue figure in the last two years. The non-COVID revenue increased 12.6 percent compared to the first quarter of 2021," said BMHS President Director Mesha Rizal Sini in a statement, Thursday, June 16.
This revenue was supported by the significant development of the company's core business, particularly the Morula IVF business unit, the market leader for IVF services in Indonesia, which continues to expand nationally. And Diagnostics, which is growing rapidly through its ability to develop a market network in non-COVID test services through strategic partnership strategies.
Mesha explained, many strategic adjustments had to be made by health care providers during the pandemic. However, apart from this, Bundamedik is always consistent with the non-COVID core business development strategy so that under any circumstances.
"We are ready with solid business fundamentals. Now along with the easing of the COVID-19 pandemic, this consistency has also become our readiness to face the dynamics of the industrial landscape," said Mesha.
According to Mesha, the achievement of the non-COVID business in the first quarter of this year is an extraordinary start for Bundamedik's efforts to continue to quickly adapt to meet the needs of public health services in the future. Moreover, along with increasing awareness of health, reflected in the significant increase in the number of non-COVID tests carried out by the community in the company's ecosystem.
During Q1 2022, the number of non-COVID tests increased by 38 percent YoY. This increase was successful due to the existence of a business model that is supported by the contribution of outlets and branches as well as the internal ecosystem in Bunda Hospital services.
The number and distribution of its outlets have also increased quite rapidly. There are now 38 Diagnos outlets, double the number in the first quarter of 2021. Going forward, Diagnos development will be intensified by adding five outlets and branches in several regions.
Other services such as Morula IVF, which has been the leading IVF service provider of choice for the Indonesian people, will also increase by 26 percent in 2021. The number of cycles outside Jakarta also continues to increase, which is 36 percent in Q1 2022 on a QoQ basis.
There was also an increase in the volume of inpatient admissions, which grew by 48 percent YoY. Another increase occurred in the number of beds, from 408 to 506 QoQ.
On the other hand, the aggressive development of the ecosystem this year has made the cost requirement even higher. Entering the beginning of 2022, BMHS has also added two hospitals, including RSJP Paramarta Bandung and RSU Citra Harapan Bekasi. Despite the general decline in revenue compared to the previous year (Rp389 billion), the company will continue to strengthen business fundamentals for the company's long-term achievement.
In order to maintain the growth momentum in the first quarter of 2022, BMHS is ready to continue its business focus through the three strategic pillars that have been launched, including expanding the ecosystem, deepening strategic partnerships, and strengthening core business.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
